No idea. But Biogen is taking a shot that hypotheses about S1 receptor in OPCs being involved in their differentiation means 2-73 could be effective there. The pathology of MS demyelination is way longer than just one step and may require a combination of therapies. This is a first step.
This is science, and all good stuff for 2-73's potential, but is not proof that "Biogen knows something". They know what we know: that 2-73 deserves a shot.
News 
Market Data 
Discover 
AI
